TLRs (Toll-like receptors) are essential modulators of the innate immune response through their ability to respond to a diverse range of conserved structures within microbes. Recent advances have been made in our understanding of the initiation of TLR signals as a result of the elucidation of crystal structures of TLRs interacting with their ligands. Most notably the structure of TLR1/2 with triacylated lipopeptide and TLR4 in a complex with LPS (lipopolysaccharide) and MD2 has been solved. These explain the basis for TLR dimerization which initiates signalling. Modifications of TLRs and their receptor proximal signalling proteins have also been uncovered. Phosphorylation of adaptor proteins and ubiquitination (both Lys 48 -and Lys 63 -linked) of TLRs, IRAKs (interleukin-1 receptor-associated kinase), Pellinos and TRAF6 (tumour-necrosis-factor-receptor-associated factor 6) have been described, which promote signalling and lead to signal termination. A detailed molecular account of the initiation and termination of TLR signalling is presented.
INTRODUCTION
TLRs (Toll-like receptors) play a critical role in the innate immune system, acting as pathogen-recognition receptors against conserved structures within microbes [1] . Ten TLRs have been identified in humans. They are type 1 transmembrane glycoproteins characterized by the presence of an LRR (leucinerich repeat domain) and a TIR [Toll/IL (interleukin)-1 receptor] domain [2] . LRRs are found in a diverse number of proteins and are involved in ligand recognition and signal transduction [3] . TLR4 was the first TLR to be identified as an orthologue of Drosophila Toll [4, 5] . TLR4 recognizes LPS (lipopolysaccharide) from Gram-negative bacteria. TLR2 can form a complex with TLR1 or TLR6 and responds to lipopeptides from a wide variety of microbes. The TLR1-TLR2 dimer responds to triacylated lipopeptides, whereas TLR2-TLR6 responds to diacylated lipopeptides. TLR3 is responsible for the recognition of dsRNA (double-stranded RNA), TLR5 recognizes flagellin, singlestranded RNA is recognized by TLR7 and TLR8, and TLR9 recognizes DNA which can be host-or pathogen-derived [6] . The intracellular TIR domain portion consists of approx. 200 amino acids. Three particular boxes are highly conserved among family members: box 1 is considered the signature sequence of the family, whereas boxes 2 and 3 contain amino acids critical for signalling. TLRs are proposed to dimerize following ligand binding, resulting in the recruitment of TIR domain-containing adaptor molecules to initiate downstream signalling through interactions within the TIR regions [7] . Four such signalling adaptors have been described: MyD88 (myeloid differentiation factor 88), Mal (MyD88 adaptor-like protein), TRIF (TIR domaincontaining adaptor inducing interferon-β) and TRAM (TRIFrelated adaptor protein). The fifth TIR adaptor SARM (sterile-α and HEAT/Armadillo motifs-containing protein) has been shown to inhibit TRIF [8] . Structures of TLR3, TLR2 and TLR4 with their ligands have been elucidated recently and provide an understanding of ligand-induced activation of TLRs [9] [10] [11] [12] .
Tight control of the TLR pathway is essential to maintain homoeostasis, since overactivation of TLRs has been linked to various infectious and inflammatory diseases. TLR engagement leads to the activation of the transcription factor NF-κB (nuclear factor κB) which regulates the induction of pro-inflammatory cytokines such as TNF (tumour necrosis factor) α, IL-1 and IL-6. It can also activate members of the MAPK (mitogen-activated protein kinase) family including p38 and JNK (c-Jun N-terminal kinase) [6] . These kinases are involved in the transcription of genes and they also regulate mRNA stability. Tight regulation of these pathways results from post-translational modification processes. Phosphorylation has long been studied as an essential modification process within TLRs. Ubiquitination is emerging as being equally important as phosphorylation for maintaining control of the TLR signalling pathways. In the present review, we discuss recent advances in structural elucidation, and also in post-translational modification of proteins in the TLR system.
LRRs AND THE TIR DOMAIN
The two core domains of the TLRs are the LRR modules (which are involved in ligand binding) and the TIR domain which is required for signal transduction. Obtaining the crystal structures of the LRRs for any of the TLRs has been long awaited and Abbreviations used: Btk, Bruton's tyrosine kinase; dsRNA, double-stranded RNA; FHA, forkhead-associated; HOIL-1L, haem-oxidized iron-regulatory protein 2 ubiquitin ligase-1; IκB, inhibitor of nuclear factor κB; IKK, IκB kinase; IL, interleukin; IRAK, IL-1 receptor-associated kinase; IRF, interferon-response factor; LPS, lipopolysaccharide; LRR, leucine-rich repeat domain; LUBAC, linear ubiquitin-chain-assembly complex; MyD88, myeloid differentiation factor 88; Mal, MyD88 adaptor-like protein; MAPK, mitogen-activated protein kinase; NF-κB, nuclear factor κB; NEMO, NF-κB essential modulator; Pam 3 CSK 4 , tripalmitoyl-cysteinyl-seryl-(lysyl) 4 ; PI3K, phosphoinositide 3-kinase; RIP, receptor-interacting protein; TAK1, transforming growth factor β-activated kinase 1; TAB, TAK1-binding protein; TIR, Toll/IL-1 receptor; TLR, Toll-like receptor; TNF, tumour necrosis factor; TRAF, TNF receptor-associated factor; TIFA, TRAF-interacting protein with a forkhead-associated domain; TRIAD3A, two RING fingers and double-RING-finger-linked 3A; TRIF, TIR domain-containing adaptor inducing interferon-β; TRAM, TRIF-related adaptor protein; Ubc13, ubiquitin-conjugating enzyme 13; UBD, ubiquitin-binding domain. 1 To whom correspondence should be addressed (email carpents@tcd.ie).
very difficult to achieve. This was overcome by the development of the so-called 'hybrid LRR technique' [10, 13] . This involved fusing hagfish variable lymphocyte receptors at the conserved LXXLXLXXN motifs within the LRR regions. Intriguingly, it has been shown that these fusions do not alter the structure or the function of the TLRs and therefore allowed the structures to be obtained. Some hybrids failed to form soluble proteins because of the formation of atomic collisions or the hydrophobic cores at the fusion sites were exposed. Therefore only hybrids which produced soluble proteins which formed stable heterodimers and could bind ligands were used for the crystallographic studies [10, 13] . LRR-containing proteins can be divided into seven subfamilies, and the TLRs belong to the 'typical' subfamily. Each LRR region consists of 24 amino acids and they possess the conserved motif XLXXLXXLXLXXNXLXXLPXXXFX and display the unique horseshoe shape associated with LRR proteins. Interestingly, the LRR regions of TLR1, TLR2 and TLR4 have been shown to deviate in their conformation when compared with other 'typical' family members [10, 13] . Their LRRs have been shown to be divided into an N-terminal region, a central region and a C-terminal region. Their central regions lack the conserved asparagine ladder normally associated with conferring stability on the horseshoe structure. This anomaly could allow these TLRs to vary their structural conformations and this could explain their ability to bind a variety of ligands as well as co-receptors which are essential for them to signal. The TIR domains of TLR1, TLR2 and TLR10 have been structurally resolved [7, 14] . The TIR domain consists of a five-stranded β-sheet surrounded by five α-helices. Key residues within the TIR domain are the BB-loop, the DD-loop and the αC-helix. Experimental work has indicated that the BB-loop is essential for TIR dimerization and subsequent adaptor recruitment. Mutations within this region abolish signalling [7, 15] . Studying TIR-TIR interactions using X-ray crystallography has been very difficult, and the only TIR-TIR interface whose structure has been resolved is that of the TLR10 dimer. It shows that the BB-loop and αC-helix on each TIR domain are the key to dimer formation. The dimer interface has been shown to be made up of a hydrophobic core which is made up of four residues of the BB-loop (Tyr 668 , Phe 672 , Pro 674 and Ile 678 ). These residues are not only involved in dimer contact, but also critical for providing stability to the BB-loop. Phe 710 and Cys 706 of the αC-helix also contribute to the hydrophobic interactions. These hydrophobic interactions are then surrounded by a hydrogen-bonding network. The structure also shows that there is a large region of the BB-loop which is not involved in the dimer formation, but is instead exposed to the surrounding solvent. This region is believed to be involved in the recruitment of other TIR domain-containing adapter proteins [12] . We have had to rely on molecular modelling and docking studies to gain insights into these interactions. It has been suggested that Mal and MyD88 bind to different regions in TLR4, allowing the formation of a heterotetrameric receptor-adaptor complex [16] . Gautam et al. [17] have suggested that the DDloop of TLR2 forms a close contact with the BB-loop of TLR1 and a mutation within the BB loop of TLR1 can interfere with signalling. It has been suggested that peptide and peptide mimetics of the BB-loop region could function as possible inhibitors of TLR signalling [14] . A key goal is to determine a TIR-TIR/adaptor-TIR structure, as this could be useful for drug design.
TLRs AND THEIR LIGANDS

TLR3 and dsRNA
The first structure of TLR3 was described independently by two groups [18, 19] . Both groups showed that the LRR region of TLR3 displays a heavily glycosylated horseshoe-shaped solenoid structure. However, each group differed in where they predicted the dsRNA would bind. Choe et al. [19] reasoned that dsRNA would bind to the convex surface on the extracellular domain as it is glycan-free and therefore the dsRNA could bind to the positively charged residues in this region. Bell et al. [18] proposed that the nucleotide-binding site is in the concave surface that possesses four potential asparagine-linked glycosylation sites and has an overall negative charge, and that it is the glycosylation of the concave surface which controls dsRNA binding. The crystal structure of TLR3 bound to dsRNA was then resolved by Lui et al. [10] . They showed that TLR3 ectodomains are monomeric in solution and that dimerization occurs upon ligand binding. Binding occurs on the N-terminal (LRR1-LRR3) and C-terminal (LRR19-LRR21) sites on the lateral side of the convex surface of TLR3 ectodomains which lie on opposite sides of the dsRNA. It is the positively charged residues on the termini of TLR3 which makes the major contributions to the interaction with the sugarphosphate backbones of dsRNA. There is binding between the two TLR3 C-terminal domains of the ectodomain and this provides stability to the dimer and is also believed to bring the TIR domains into contact, thus allowing for the downstream signalling cascade to occur.
TLR1/2
The crystal structure of the extracellular domains of TLR2 and TLR1 and a synthetic triacylated lipopeptide Pam 3 CSK 4 [tripalmitoyl-cysteinyl-seryl-(lysyl) 4 ] has been described [11] . Similarly to that observed for TLR3, Jin et al. [11] could show that, without bound ligand, TLR1 and TLR2 resolved as monomers; however, when Pam 3 CSK 4 was added, the TLRs formed stable heterodimers. Pam 3 CSK 4 consists of three lipid chains; two were found to insert into a hydrophobic pocket in TLR2 and the other chain inserts into a narrow hydrophobic channel in TLR1. Both pockets are located between the central and C-terminal domains of the convex region. This was found to be quite unusual as most ligand-binding sites on LRR proteins to date have been found to be on the concave surfaces. Further stability within the TLR1-TLR2 heterodimer and Pam 3 CSK 4 is achieved by hydrophobic, hydrogen-bonding and ionic interactions between TLR1 and TLR2 [11] .
TLR4
A crystal structure of the TLR4-MD2 complex binding the antagonist Eritoran has been described [20] . TLR4 requires its co-receptor MD2 in order to recognize LPS [21] . LPS is made up of a lipid A portion, which is the endotoxic component, a core oligosaccharide and a so-called O-antigen which is also a carbohydrate. The lipid A portion consists of phosphorylated diglucosamine and four to seven acyl chains. Synthethic lipid A moieties consisting of six lipid chains and two phosphate groups are optimal for endotoxicity [22, 23] . Lipid A containing five or seven acyl chains is 100-fold less active. Eritoran is a synthetic molecule derived from the lipid A component of a nonpathogenic LPS from Rhodobacter sphaeroides [24] . It functions as an antagonist of TLR4 signalling. Eritoran consists of four lipid chains. The crystal structure obtained shows that all four acyl chains of Eritoran bind to a hydrophobic pocket in MD2 and it does not bind to TLR4 [20] . This observation suggested that LPS only binds to MD2 and no direct interaction between Eritoran and TLR4 occurs. This has been shown recently not to be the case [12] . The much anticipated crystal structure of TLR4-MD2 binding to LPS has finally been solved [12] ( Figure 1A ). Park et al. [12] elegantly show that, without LPS, TLR4 and MD2 associate, but dimerization of the TLR4-MD2 complex with another TLR4-MD2 complex only occurs following binding of LPS. The structure shows LPS binding to two copies of TLR4 and MD2 arranged symmetrically. The structure of MD2 shows that it consists of a β-cup fold structure consisting of two antiparallel β-sheets, and it is this structure which forms the hydrophobic pocket to allow LPS to bind. In order for dimerization to occur, TLR4 forms hydrophobic and hydrophilic interactions with LPS which also associates with the Phe 126 and Leu 87 loops of MD2. Five of the lipid chains of LPS are buried within the hydrophobic pocket of MD2 in a manner similar to Eritoran. The remaining lipid chain (referred to as R2, Figure 1B ) is on the surface of MD2 where it forms a hydrophobic interaction with phenylalanine residues on TLR4 as shown in Figure 1 . The binding of LPS causes structural changes in MD2 mainly on the Phe 126 loop, leading to hydrophilic interactions between MD2 and TLR4, stabilizing the complex further. It appears that the Phe 126 loop of MD2 is critical for the activation of the TLR4 complex in response to LPS stimulation. Phe 126 is at the core of the dimerization interface following LPS stimulation. The crystal structure of TLR4-MD2 bound to the antagonist Eritoran shows that the Phe 126 loop of MD2 was exposed to the surrounding solvent [20] (Figure 1C ). This would suggest that this is the key to understanding why Eritoran is an antagonist. Clearly the structural change which occurs to the Phe 126 loop of MD2 following LPS stimulation is essential for the formation of the dimers and subsequently the initiation of downstream signalling [12] (Figure 1D ). Mutational analysis of the Phe 126 loop of MD2 also supports this finding. If Phe 126 is mutated, it prevents dimerization and downstream signalling does not occur [20, 25] .
The phosphate groups which are known to be critical for LPS activity form ionic interactions with positively charged residues on both TLR4 and MD2. The extra two lipid chains in LPS compared with Eritoran results in a displacement of the phosphorylated glucosamines and this allows the phosphate groups to associate with TLR4 and MD2.
Obtaining the crystal structure of TLR4 and LPS has helped us to understand the anomaly that lipid IVa which acts as an antagonist in humans could act as a mild agonist for murine or equine TLR4. Walsh et al. [26] show that changing Arg 385 in equine TLR4 to glycine abolishes the agonist activity of lipid IVa [26] . From the crystal structure of TLR4 and LPS, the 1-phosphate of LPS and the positively charged arginine residue in equine TLR4 could be enough to allow stronger interactions with the 1-phosphate of lipid IVa, thereby conferring agonistic activity of lipid IVa in horse. These data again show the importance of the correct positioning of the phosphate groups in LPS for activation of the TLR4 complex.
All structures of TLRs bound to their ligands reveal a common 'M'-shaped architecture which is shown in Figure 2 . The C-termini of the extracellular domains converge, which should therefore allow the interaction between the TIR domains to occur and initiate downstream signalling events [27] . Additional structural studies around the TIR interactions should improve The ectodomains of TLR3 are monomeric in solution until they bind to dsRNA and dimerization occurs. The dsRNA interacts at both the N-and C-termini of each TLR3 ectodomain. The binding occurs on the glycan-free surface of each ectodomain [10] . The binding of dsRNA causes the C-terminal domains to associate and this adds stability to the dimer and is proposed to bring the two TIR domains into contact to initiate downstream signalling. Two downstream signalling pathways are subsequently triggered, leading to activation of NF-κB and IRF3. TLR4 and MD2 interact before stimulation with LPS. When LPS is added, it leads to dimerization of two TLR4-MD2 complexes. Five acyl chains of LPS bind the hydrophobic pocket of MD2, while the sixth acyl chain (in red) associates with TLR4 [12] . Dimerization of the tetrameric complex brings the TIR domains together and initiates downstream signalling through the adaptor molecules MyD88, Mal, TRIF and TRAM, which leads to the activation of the transcription factor NF-κB and the release of pro-inflammatory cytokines. TLR2 can heterodimerize with TLR1 and respond to triacylated lipopeptides or it can bind to TLR6 and respond to diacylated lipopeptides. Both complexes utilize the adaptors MyD88 and Mal to initiate downstream signalling, which leads to the activation of NF-κB and the release of pro-inflammatory cytokines. IFN, interferon; NAP1, nucleosome assembly protein 1; RANTES, regulated upon activation, normal T-cell expressed and secreted; TAK1, transforming growth factor β-activated kinase 1.
our understanding of the downstream signalling events following ligand interactions.
POST-TRANSLATIONAL MODIFICATIONS IN TLRs
The other important biochemical aspect of TLR signalling where there has been recent progress is in post-translational modification. As mentioned above, tight control of TLR signalling pathways is essential to maintain homoeostasis. Control is provided by phosphorylation and ubiquitination.
Phosphorylation
Tyrosine phosphorylation of TLRs
Experimental evidence to date suggests that phosphorylation is an essential part of the formation of multiprotein complexes in TLR signalling at the cell membrane. Tyrosine phosphorylation of TLR2, TLR3, TLR5 and TLR4 has been shown to be essential for initiation of downstream signalling events [28] [29] [30] [31] . Tyr 616 and Tyr 761 are essential for TLR2 signalling, as a double mutant of these residues abolishes NF-κB-dependent reporter activity [28] . A study of the phosphorylation of TLR3 revealed that Tyr 759 and Tyr 858 are important as mutations resulted in loss of signalling in response to dsRNA [28] . A key kinase linked to most TLR downstream signalling is PI3K (phosphoinositide 3-kinase). The p85 subunit of PI3K is capable of binding to phosphotyrosine residues via its SH2 (Src homology 2) domain. Mutants of Tyr 616 and Tyr 761 in TLR2 prevent binding to the p85 subunit of PI3K and therefore results in an inhibition of NF-κB signalling [28] . Phosphorylation of Tyr 759 on TLR3 has been shown to be required to recruit PI3K which binds to its downstream kinase Akt, and this is needed for IRF (interferon-response factor) 3 phosphorylation and activation [28] . A putative PI3K-binding site in TLR5 has been localized to Tyr 798 . Mutation of this residue inhibits signalling in response to flagellin. Tyr 674 and Tyr 680 are two phosphorylation sites in TLR4. If these sites are mutated to alanine they inhibit signalling, presumably by altering the TLR4-MyD88 interaction [28] .
Phosphorylation of adaptor molecules
Much work has been carried out showing the post-translational modifications of the adaptor molecules Mal and TRAM. Mal is utilized by both TLR4 and TLR2 and it is subject to a number of modifications. Mal has been shown to possess a PtdInsP 2 -binding domain, which enables Mal to be localized to the plasma membrane where it can act as a bridging adaptor to MyD88 [32] . Mal undergoes tyrosine phosphorylation by Btk (Bruton's tyrosine kinase) [33] . Tyr 86 and Tyr 187 are important in Mal as mutant forms acted as dominant-negative inhibitors of NF-κB activation following LPS stimulation [28] . An additional study has shown that Tyr 86 , Tyr 106 and Tyr 159 are important residues, as mutagenesis of these residues impaired Mal phosphorylation, affected its interaction with Btk and also impaired downstream signalling [34] .
TRAM acts as a bridging adaptor for TRIF in the TLR4 signalling complex and, like Mal, it undergoes a number of modifications [35] . TLR4 has been shown to be capable of signalling from the plasma membrane and from the endosome. TRAM has been shown to traffic to early endosomes where it binds TRIF and results in the activation of TBK-1 {TANK [TRAF (TNFreceptor-associated factor)-associated NF-κB activator]-binding kinase 1} which phosphorylates IRF3, leading to the induction of interferon-β [32] . Recently, a splice variant of TRAM has been described termed TRAM adaptor with gold domain (TAG), which displaces TRIF from TRAM in the late endosome to limit signalling [36] . TRAM has been shown to undergo myristoylation at its N-terminus, allowing it to localize to the plasma membrane [37] . TRAM has been shown to be phosphorylated on Ser 16 by protein kinase Cε following LPS stimulation [38] .
The role of IRAKs (IL-1 receptor-associated kinases)
Following receptor activation and adaptor recruitment, there are a number of signalling molecules involved downstream which are regulated by phosphorylation. Four IRAKs have been identified: IRAK-1, IRAK-4, IRAK-2 and IRAK-M. IRAK-1 and IRAK-4 are serine/threonine kinases. IRAK-4 has been shown to phosphorylate IRAK-1, and this plays a key role in TLR signalling cascades. IRAK-1 has been shown to activate NF-κB, not through the classical pathway involving degradation of IκB (inhibitor of NF-κB), but through facilitating the phosphorylation of p65/RelA. This was confirmed by studies on IRAK-1-knockout cells, which showed impaired phosphorylation of p65/RelA, whereas IκB degradation was normal [39] . IRAK-1 also appears to be important for phosphorylation of IRF5-IRF7, as IRAK-1-knockout cells show reduced activation of IRF5-IRF7 following stimulation with TLR7, TLR8 and TLR9 ligands [40, 41] . As mentioned above, IRAK-4 phosphorylates IRAK-1. Once phosphorylated, IRAK-1 can then continue to undergo autophosphorylation followed by degradation [42] . IRAK-4 is more important for the activation of NF-κB than IRAK-1. This was demonstrated by examining IRAK-4-knockout mice which showed impaired NF-κB activation and reduced cytokine production in response to TLR ligands [43] . The kinase activity of IRAK-4 has also been shown to be essential for signalling, as overexpression of the kinase-dead form of IRAK-4 resulted in a reduction in LPS-induced NF-κB activation [44] . Children with an IRAK-4 deficiency suffer from persistent pyogenic bacterial infections and do not respond to a number of TLR ligands [45] ; however, intriguingly, children with this deficiency return to normal as adults [21] . Clearly, IRAK-4 is essential for protection in children, but is expendable in adults. IRAK-2 and IRAK-M are pseudokinases, and IRAK-M has been shown to act as a negative regulator of TLR signalling [46] . IRAK-M-knockout macrophages displayed higher NF-κB activation and increased pro-inflammatory cytokines in response to TLR ligands [46] . IRAK-2 can interact with TRAF6, MyD88 and Mal and can activate NF-κB. Studies carried out on IRAK-2-knockout mice indicate that IRAK-2 is needed for optimal responses to TLR ligands and the mice produce less IL-6 and TNFα [47] . However, the mice show normal MAPK and early-phase NF-κB activation, which is probably due to redundancy with IRAK-1. IRAK-2/ IRAK-1 double knockouts are completely resistant to LPS or CpG-induced septic shock and macrophages show reduced responses to all TLR ligands except TLR3. These results indicate that IRAK-1 and IRAK-2 work together to mount appropriate responses to TLR stimulation.
Ubiquitination
Ubiquitination, like phosphorylation, is a reversible covalent modification involved in the regulation and localization of target proteins. Ubiquitination is emerging as a key process required for regulating the immune system. Phosphorylation has often been shown to precede ubiquitination, and a good example is IκB, which initially gets phosphorylated in order to release NF-κB to the nucleus. IκB is subsequently degraded by the proteasome to terminate the signal. For the remainder of this review, we discuss the various types of ubiquitination and the proteins involved in regulating TLR signalling.
Ubiquitin
Ubiquitin consists of 76 amino acids and is highly conserved across species. It covalently links to one or more lysine residues on target proteins through the following three steps: initially, a ubiquitin-activating enzyme (E1) processes an inactive ubiquitin precursor molecule. The activated molecule is then transferred to a cysteinyl group on a ubiquitin-conjugating enzyme (E2). The final step involves a ubiquitin-protein ligase (E3) whose job is to transfer the ubiquitin from the E2 on to a lysine residue on a substrate. Since ubiquitin contains seven lysine residues (Lys 6 [48] . Proteins can also undergo mono-ubiquitination and linear ubiquitination in more detail. Both processes are covered in more detail below. Figure 3 illustrates the four known types of ubiquitination including examples of each in the TLR system.
Mono-ubiquitination
Proteins which can bind to ubiquitin contain UBDs (ubiquitinbinding domains) and can be referred to as ubiquitin receptors. Ubiquitin receptors can interact directly with mono-ubiquitin or they can interact with polyubiquitin chains on proteins which have undergone ubiquitination [49] . Often, ubiquitin receptors are themselves mono-ubiquitinated, and this is known as coupled mono-ubiquitination. It has also been proposed that ubiquitin
Figure 3 Ubiquitination modifications, including examples within the TLR signalling pathway
The process of ubiquitination occurs when ubiquitin covalently links to one or more lysine (K) residues on target proteins through the use of the following three proteins: a ubiquitin-activating enzyme (E1), a ubiquitin-conjugating enzyme (E2) and a ubiquitin-protein ligase (E3). Since ubiquitin (Ub) contains seven lysine residues and each of these can be conjugated to the C-terminus of another ubiquitin, it enables this process to be repeated to form polyubiquitin chains. This can result in Lys 48 receptors can recruit ubiquitin machinery to promote coupled mono-ubiquitination. The process of mono-ubiquitination of a target protein can affect its conformation and ability to interact with other proteins. It can also affect the target protein's subcellular localization and activity and can cause the protein to undergo lysosomal degradation [50] . In relation to TLR signalling, the mono-ubiquitination of histone H2A has been linked to the repression of specific chemokines in macrophages affecting cell migration in response to TLR activation [51] . It has been shown that ubiquitin receptors which undergo mono-ubiquitination are involved in intramolecular interactions between mono-ubiquitin and their UBDs and are therefore inhibited as a mechanism for control within the pathway [52] .
NEMO (NF-κB essential modulator) and linear ubiquitination
An additional form of ubiquitination known as linear ubiquitination has of late been linked to NF-κB activation. Linear ubiquitination chains are unique in that this linkage does not involve lysine linkages; instead, the linkages are between the N-and C-terminus of each ubiquitin [53] . NEMO has been known to undergo ubiquitination, and it has been shown recently that this is linear ubiquitination, which is essential for its ability to activate NF-κB and not the MAPK pathway [54] [55] [56] . NEMO had been shown previously to undergo Lys 63 -linked polyubiquitination, resulting in the recruitment of the TAK1 (transforming growth factor β-activated kinase 1)-TAB (TAK1-binding protein) 1-TAB2 complex. Ubc13 (ubiquitin-conjugating enzyme 13) encodes an E2 enzyme which is essential for generating Lys 63 linked chains, and, when the Ubc13 conditional knockout mouse was generated, it had very little effect on NF-κB activation, thus suggesting the presence of a Ubc13-independent NF-κB activation pathway which now appears to involve linear ubiquitination [37] . Tokunaga et al. [54] have shown that the LUBAC (linear ubiquitin-chain-assembly complex) which consists of two RING finger proteins HOIL-1L (haem-oxidized iron-regulatory protein 2 ubiquitin ligase 1) and HOIP (HOIL-1L-interacting protein) are involved in forming head-to-tail linear polyubiquitin chains on NEMO. They have shown that it is Lys 285 and Lys 309 in NEMO that are linearly ubiquitinated by LUBAC. As mentioned above, two additional papers have been published recently showing that the UBAN [ubiquitin binding in ABIN (A20-binding inhibitor of NF-κB) and NEMO] motif present in NEMO binds linear ubiquitin chains with stronger affinity than Lys 63 -linked chains [55, 56] . However, the exact physiological functions for linear ubiquitination are unknown. It is proposed that the linear ubiquitin chains may act as scaffolds to recruit activating complexes. All results indicate that linear ubiquitination of NEMO is essential for NF-κB activation, but is not required for the activation of MAPK pathway.
Ubiquitin ligases
The final area that we consider are the key ubiquitin ligases associated with the TLRs: TRAF6, TRIAD3A (two RING fingers and double-RING-finger-linked 3A), A20 and, the most recently described, members of the Pellino family. [60] . Mutations within the TRAF6-binding site of TIFA inhibited activation of IKK in vitro. These results would suggest that TIFA is needed for TRAF6 oligomerization, and this could be essential for the activation of the E3 ligase activity of TRAF6. Recently, Keating et al. [61] have shown that IRAK-2 is the key IRAK and not IRAK-1 in mediating TRAF6 polyubiquitination in TLR signalling. They showed that A52, which is a known inhibitor of TLR signalling, achieves this inhibition by targeting IRAK-2. They also showed that mutants of IRAK-2 were unable to activate NF-κB or promote TRAF6 ubiquitination. Clearly, TRAF6 Lys 63 -linked polyubiquitination is an essential part of TLR signalling; however, much work is still needed to determine whether there are more proteins than TIFA and IRAK-2 involved in TRAF6 oligomerization and subsequent activation.
TRIAD3A. TRIAD3A is a ubiquitin ligase which has been shown to be involved in the ubiquitination and degradation of TLRs [62] . The protein contains a TRIAD domain often found in E3 ligases. TRIAD3A has been shown to promote the ubiquitination and degradation of TLR9, TLR4 and, to a lesser extent, TLR3 and TLR5. TRIAD3A did not affect TLR2 as the two proteins are unable to interact. Knockdown of TRIAD3A resulted in enhanced responses to LPS, flagellin and CpG DNA, suggesting that, overall, TRIAD3A can function as a negative regulator of TLR signalling.
Pellinos. The Pellinos are the most recent family of proteins to emerge as key players in TLR signalling. There are three members of the Pellino family: Pellino1, Pellino2 and Pellino3. There are also splice variants of Pellino 3: Pellino3L and Pellino3S. They have all been shown to be E3 ligases. Pellinos possess a C-terminal RING-like domain which confers E3 ubiquitin ligase activity. Recently, the crystal structure of Pellino2 has been resolved and it shows that the Pellinos also possess a phosphothreonine-binding FHA domain [63] . The main function of the Pellinos within TLR signalling is that they bind and cause Lys 63 -linked polyubiquitination of IRAK-1. IRAK-1 and IRAK-4 have also been shown to phosphorylate the Pellino proteins which then undergo Lys 48 -linked polyubiquitination, resulting in their degradation [64] [65] [66] . The Pellino proteins have also been shown to bind to TRAF6 and TAK1. This is an interesting observation, since Pellinos can activate IRAK-1 which is known to bind to TRAF6, suggesting that the Pellinos are essential proteins needed for the activation of this complex [67] .
The literature to date on the role of each family member of the Pellinos have resulted in conflicting data. The role of Pellino1 in the activation of NF-κB has been questioned; however, it does appear to have a role in IL-1-induced NF-κB, as knockdown of Pellino1 impairs this activation [44] . Pellino1 has been shown not to be involved in the MAPK pathway [44] . Again, the role of Pellino2 seems quite unclear. Overexpression of Pellino2 drives both the NF-κB and the MAPK pathways [68] .
A number of papers have reported on the function of Pellino3. Butler et al. [64] show that of the three family members Pellino3 has the most E3 ligase activity and it promotes Lys 63 -linked polyubiquitination of IRAK-1. Previous reports suggested that IRAK-1 is degraded following stimulation [42, 44] . However, the recent work on Pellinos would suggest that IRAK-1 is Lys 63 -and not Lys 48 -linked ubiquitinated. The activation of IRAK-1 is believed to bring in the IKK complex through recruitment of NEMO to Lys 63 -linked chains on IRAK-1. TAK1 is recruited to the Lys 63 -linked polyubiquitin chains on TRAF6, and these linkages allow the IKK complex and TAK1 to come into close proximity. TAK1 can then activate the IKKs and stimulate the downstream signalling events [44] . Interestingly, a recent paper has been published which suggests that Pellino3 can act as a negative regulator of TAK1-mediated activation of NF-κB [69] . This suggests that there is one ubiquitination site on IRAK-1 ( 48 -linked polyubiquitination to prevent IRAK-1 degradation and, in doing so, inhibit IL-1-induced TAK1 activation by preventing the TRAF6-TAK1-TAB3-TAB3 complex from translocating from the membrane to the cytosol. This all reverts to the role of IRAK-1 and whether degradation or activation is required for the subsequent activation of TAK1 and the IKK complex. Clearly, more work is needed to clarify the role of the Pellinos. The generation of Pellino-knockout mice will hopefully shed some much needed light on the exact functions of these family members within IL-1 and TLR signalling.
A20. A20 can act as both a deubiquitinating and a ubiquitinating enzyme. A20 can remove ubiquitin from TRAF6, allowing TRAF6 to be recycled as well as terminating TLR signals [63, 70] . Results from A20-knockout cells show enhanced NF-κB activation in response to TLR2, TLR4 and TLR9 ligands. A20 has also been shown to be capable of simultaneously removing Lys 63 -linked polyubiquitin chains from RIP (receptorinteracting protein) and adding Lys 48 -linked chains resulting in RIP degradation [71] .
FINAL CONCLUSIONS
The TLR signalling pathways are highly complex. Tight control is needed in order to maintain homoeostasis. Solving the crystal structures of TLRs binding to their ligands has allowed us to understand further the initiation of TLR signals. The three structures (TLR3, TLR1-TLR2 and TLR4) clearly elucidate the molecular basis for TLR dimerization and subsequent signal transduction. There are a number of neutralizing antibodies available to block signalling and, more recently, there are small molecules such as Eritoran for TLR4, which are capable of inhibiting signalling. Understanding how ligands bind their receptors through solving crystal structures will allow for better inhibitors to be designed to block this process.
Part of the complexity within TLR signalling comes from the many post-translational modifications which occur and are summarized in Figure 4 . The role of mono-ubiquitination and linear ubiquitination is emerging as an exciting area of regulation for TLR signalling. Further studies are needed to fully understand all the proteins responsible for the phosphorylation and ubiquitination events involved in the regulation of TLR signalling. Much work has already been done in an attempt to develop drugs to exploit proteins involved in phosphorylation and ubiquitination, since both processes when dysregulated can lead to disease. Targeting components of phosphorylation has yielded clinical success. Ubiquitin ligases have been a target for potential drugs to treat cancer; however, to date, none of the approaches has yielded significant clinical advances [72] . Targeting ubiquitination may prove difficult owing to the fact that these processes occur alongside many other signalling pathways and E3 ligases may not be specific enough as targets [72] . However, further elucidation of the structural and molecular basis for the signalling should help in the ultimate goal of targeting these pathways therapeutically.
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